CARVYKTI: payments to doctors
Payments that named CARVYKTI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $10.3M
- Providers
- 9,651
- Transactions
- 27,354
- Average per transaction
- $375
The per-transaction average — $375 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 9,651 providers the average total is $1,064, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $8,866,187 | 86.4% |
| Legend Biotech USA Inc. | $419,646 | 4.1% |
| Janssen Research & Development, LLC | $383,473 | 3.7% |
| Janssen Global Services, LLC | $350,080 | 3.4% |
| Janssen Scientific Affairs, LLC | $245,097 | 2.4% |